Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript
Pacira BioSciences, Inc. ( PCRX ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Susan Mesco - Head of Investor Relations Frank Lee - CEO & Director Brendan Teehan - Chief Commercial Officer Shawn Cross - Chief Financial Officer Jonathan Slonin - Chief Medical Officer Conference Call Participants Leszek Sulewski - Truist Securities, Inc., Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Dennis Ding John Gionco - Needham & Company, LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Pacira BioSciences Third Quarter Earnings Conference Call.
Pacira BioSciences, Inc. (PCRX) Q1 2025 Earnings Call Transcript
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Jonathan Slonin - Chief Medical Officer Shawn Cross - Chief Financial Officer Brendan Teehan - Chief Commercial Officer Conference Call Participants Anish Nikhanj - RBC Capital Markets Gary Nachman - Raymond James Hardik Parikh - JPMorgan Serge Belanger - Needham Operator Good day, and thank you for standing by. Welcome to the First Quarter 2025 Pacira BioSciences Earnings Conference Call.
Pacira (PCRX) Q1 Earnings Surpass Estimates
Pacira (PCRX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.62 per share a year ago.
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study
Pacira doses the first patient in the phase II ASCEND study of PCRX-201 gene therapy for OA of the knee.
Pacira Surges 66.8% in Six Months: How Should You Play the Stock?
PCRX has put up a strong performance in six months with shares rallying 66.8%. However, its sole dependence on Exparel for growth is a concern.
Pacira BioSciences: Back On An Uptrend After Positive Developments
Pacira BioSciences, Inc.'s stock is up 33% since my last “Buy” rating, driven by strategic moves and market overreaction correction. The company has secured a new patent for its lead pain therapeutic, Exparel, delaying generic market entrants, and potentially protecting its market share until mid-next decade. Vertex's Journavx launch may boost awareness for non-opioid pain relief, benefiting Pacira's Exparel under the NOPAIN Act.
Bull of the Day: Pacira BioSciences (PCRX)
Earnings moving in the right direction and a bounce off technical support sets this stop up nicely.
Pacira Q4 Earnings Top, Revenues Miss Despite Exparel Sales Growth
PCRX reports mixed fourth-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.
Pacira BioSciences, Inc. (PCRX) Q4 2024 Earnings Call Transcript
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q4 2024 Results Conference Call February 27, 2025 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Shawn Cross - Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Gregory Renza - RBC Capital Markets Gary Nachman - Raymond James Hardik Parikh - JPMorgan Operator Good day, and thank you for standing by.
Compared to Estimates, Pacira (PCRX) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pacira (PCRX) Tops Q4 Earnings Estimates
Pacira (PCRX) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.89 per share a year ago.
Seeking Clues to Pacira (PCRX) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Pacira (PCRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
